ArticleJournal of asthma and allergy2026
Characteristics of Patients with Severe Uncontrolled Asthma in Saudi Arabia: A Cross-Sectional Study.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe asthma poses significant morbidity and healthcare burden, with the eosinophilic phenotype being particularly prevalent. This study aims to characterize the demographic and clinical profiles of severe eosinophilic asthma patients in a Saudi Arabian cohort involving multiple centers in the country. Methods: A cross-sectional analysis of a prospective cohort of 268 patients with severe eosinophilic asthma, eligible for benralizumab treatment, was analyzed from the Saudi Arabian Ministry of Health database. Demographic data, biomarker profiles, and historic disease and medication burden were examined and stratified by various parameters including city/region, eosinophil count, and type 2 inflammatory comorbidities. Results: Patients were predominantly female (66.4%), with an average age of 45.3 years, and had a median BMI of 27.7 kg/m2. The majority were never smokers, and about one-third had type 2 inflammatory comorbidities. High exacerbation rates (median of 5 exacerbations per year) and frequent healthcare utilization were noted despite high-dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) treatment. Nearly 20% of patients were on maintenance oral corticosteroids. The median blood eosinophil count was 656 cells/μL, indicating a high prevalence of severe eosinophilic asthma (defined as a blood eosinophil count ≥ 150 cells/μL. Conclusion: This study confirms the substantial burden of severe eosinophilic asthma in the Saudi population, with significant exacerbation rates and healthcare resource use despite conventional therapy. The data suggest a potential role for benralizumab in improving disease outcomes for severe eosinophilic asthma. Further research is needed to evaluate the efficacy and cost-effectiveness of benralizumab in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.